1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Kalaris Therapeutics Inc

Kalaris Therapeutics Inc

KLRS
Kalaris Therapeutics IncUS flagNASDAQ Global Market
2.70
USD
-0.15
- -
58.93MMarket Cap
Kalaris Therapeutics Inc
KLRS
(NASDAQ Global Market)

Recent

price

2.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
-11.64
-11.05
-3.7
-2.85
-2.01
Basic EPS, GAAP
-7.35
-10.62
-1.11
-2.53
-1.86
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
-1.62
-2.41
-5.17
3.44
2.42
Book Value per Share
-1.62
-2.41
-5.17
3.44
2.42
Tangible Book Value per Share
1
1
19
15
22
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
-15
-15
-69
-43
-44
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
-2
-1
-22
109
87
Working Capital
3
- -
- -
1
1
LT Debt
-30
-45
-97
79
58
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-79.91
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
24
Market Capitalization
193
133
97

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
119
98
96
Cash, Cash Equivalents & STI
118
97
94
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
10
8
9
Payables & Accruals
8
7
8
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-181.57%
Free Cash Flow
- -
- -
86.6%
Net Income, GAAP
- -
- -
-37.2%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.52
-4.18
-28.16
- -
-3.7
2025
-2.52
-0.61
-0.64
- -
-2.85
2026
-0.46
-0.48
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Kolon TissueGene, Inc. (950160.KQ)
Advagene Biopharma Co., Ltd. (6709.TWO)
European Medical Solutions (0RGO.L)
Syndax Pharmaceuticals, Inc. (SNDX)
Aptahem AB (publ) (APTA.ST)
Pathfinder Cell Therapy, Inc. (PFND)
Business
Kalaris Therapeutics Inc. functions as a clinical-stage biopharmaceutical firm. The company is dedicated to advancing and commercializing innovative treatments for widespread retinal conditions. Its primary focus is on TH103, a distinguished anti-vascular endothelial growth factor (VEGF) investigational therapy. Engineered for enhanced VEGF inhibition and extended retention within the retina, TH103 acts as a fully humanized recombinant fusion protein, functioning as a decoy receptor. This therapy is currently being assessed in Phase 1 clinical trials for neovascular age-related macular degeneration (nAMD), with plans to expand its application to other neovascular and exudative retinal diseases, including diabetic macular edema (DME) and retinal vein occlusion (RVO). Kalaris recently completed a merger, securing substantial funding to support its ongoing clinical development efforts. The objective is to mitigate the limitations of existing therapies, aiming to lessen the treatment burden on patients.

Company News

Company News APIChatGPT

  • defenseworld.net

    Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75

  • globenewswire.com

    Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

  • globenewswire.com

    Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

  • defenseworld.net

    Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened

  • globenewswire.com

    KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders

  • globenewswire.com

    Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

  • globenewswire.com

    Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

  • globenewswire.com

    Kalaris Appoints Laurie Keating to Board of Directors

  • globenewswire.com

    Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

  • globenewswire.com

    Kalaris to Present at Clinical Trials at the Summit 2026

  • globenewswire.com

    Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

  • globenewswire.com

    Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

  • defenseworld.net

    Kalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Buys 479,847 Shares of Stock

  • seekingalpha.com

    Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

  • seekingalpha.com

    Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

  • globenewswire.com

    Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

  • globenewswire.com

    Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

  • newsfilecorp.com

    Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

  • globenewswire.com

    Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

  • globenewswire.com

    Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer